ropinirole IR / Generic mfg. - LARVOL DELTA

Exploring the Pharmaceutical Significance and Analytical Landscape of Ropinirole: An In-Depth Review of an Indole-Based Dopaminergic Therapeutic Agent. (PubMed, Crit Rev Anal Chem) - "This review bridges pharmacological and analytical perspectives, advocating for next-generation platforms to enhance method sensitivity, selectivity, and reproducibility. Adopting validated, stability-indicating approaches will strengthen regulatory acceptance and improve therapeutic monitoring and quality control (QC) for ropinirole formulations."

Journal • Review • CNS Disorders • Movement Disorders • Parkinson's Disease • Restless Legs Syndrome • Sleep Disorder • CYP1A2

Drug discovery research with the iPSC models of neurodegenerative diseases. (PubMed, Neurosci Res) - "In addition, clinical trials based on research with iPSCs have been conducted: bosutinib, ropinirole and ezogabine for ALS, WVE-004 and BIIB078 for ALS with frontotemporal dementia (ALS/FTD), and bromocriptine for familial AD. Finally, we also wish to mention screening studies utilizing artificial intelligence (AI)."

Journal • Review • Alzheimer's Disease • Amyotrophic Lateral Sclerosis • CNS Disorders • Dementia • Frontotemporal Lobar Degeneration

A Restless Drug: Ropinirole-Induced Pancreatitis in a RLS Patient (ACG 2025) - "Timely identification and withdrawal of the offending agent can prevent recurrence and complications. Further pharmacovigilance and mechanistic research are needed to clarify the true incidence and pathophysiology of dopamine agonist–associated pancreatitis."

Clinical • CNS Disorders • Gastroenterology • Immunology • Movement Disorders • Pancreatitis • Parkinson's Disease • Restless Legs Syndrome • Sleep Disorder

Trihexyphenidyl as a Treatment for Severe Freezing of Gait in Parkinson's Disease: A Case Report (MDS Congress 2025) - "Prior treatments—including Sinemet, Rotigotine, Ropinirole, Clonazepam, Amantadine, and Rasagiline—were ineffective and caused additional symptoms like tremors and fatigue. To date, no published case studies have demonstrated significant improvement in a patient's freezing of gait (FoG) with trihexyphenidyl (Artane), except for a single case reported in 2020 (1). That study described a patient with a FoG-like gait disturbance characterized by direction-associated FoG occurring exclusively during forward walking, who experienced gait improvement with trihexyphenidyl. However, the patient's leg symptoms were more consistent with task-specific dystonia, as subsequent surface electromyography (EMG) studies revealed dystonic co-contraction in the leg during forward walking in the OFF-state, but not during backward walking or side-stepping, supporting a diagnosis of task-specific dystonia."

Case report • Clinical • CNS Disorders • Dystonia • Movement Disorders • Parkinson's Disease

Survey of knowledge and training needs of professionals in nursing homes for Parkinson's disease (MDS Congress 2025) - "In addition, dopaminergic agonists are little known to professionals (Sifrol 25% and Requip 21%). Nursing home professionals are familiar with certain aspects of Parkinsonian syndromes. In view of the results obtained, work needs to be undertaken to adapt to specific specific requests, in order to promote expertise towards Parkinsonian patients."

CNS Disorders • Depression • Mood Disorders • Movement Disorders • Parkinson's Disease • Psychiatry

A Case of "Rabbit" Syndrome with Concomitant Tongue Tremor (MDS Congress 2025) - " N/A A 58-year-old Hispanic female with a history of restless leg syndrome (RLS) on ropinirole and depression on aripiprazole, lamotrigine, and paroxetine initially presented for worsening RLS...Ropinirole was replaced with pregabalin with marked improvement in RLS symptoms...Movements significantly improved after starting carbidopa/levodopa... The movement pattern of the lips in this patient is consistent with the known phenomenology of "rabbit" syndrome. However, the concomitant re-emergent tongue is atypical with this syndrome and it is more commonly a feature of Parkinson's disease tremor. Given the possible shared mechanism between RS and DIP, this case may represent a co-occurring phenomenon or support RS being part the DIP spectrum."

Clinical • Preclinical • CNS Disorders • Depression • Movement Disorders • Parkinson's Disease • Psychiatry • Restless Legs Syndrome • Sleep Disorder

Diagnosis and Treatment of Augmentation Syndrome Secondary to Ropinirole: A Case Report. (PubMed, Cureus) - "In this patient, a 61-year-old Caucasian female with a 20-year history of RLS, treated with gabapentin 300 mg twice daily and ropinirole 0.25 mg three to four times per day, augmentation was observed, likely due to long-term treatment with the dopamine agonist ropinirole in combination with low vitamin D levels. This case highlights the importance of recognizing augmentation in patients on long-term dopaminergic therapy and considering contributory factors such as vitamin D deficiency. Early identification and individualized treatment adjustments are essential to improving outcomes."

Journal • Movement Disorders • Restless Legs Syndrome • Sleep Disorder

Advanced P407/Tw80/βCD based Nasal Powders of Ropinirole Hydrochloride for Nose-to-Brain Delivery in Parkinson's Disease: Preparation and Comprehensive In Vitro and Ex Vivo Evaluation. (PubMed, AAPS J) - "This study demonstrates the potential of these formulations for effective nose-to-brain drug delivery. Ongoing in vivo pharmacokinetic studies are being conducted to assess the performance of the optimal formulations in an appropriate animal model."

Journal • Preclinical • CNS Disorders • Movement Disorders • Parkinson's Disease

Othello Syndrome Induced by Dopamine Agonists in Parkinson's Disease: A Case Report. (PubMed, Case Rep Psychiatry) - "Case Presentation: A 69-year-old man with a longstanding diagnosis of PD developed OS after transitioning from levodopa/carbidopa to ropinirole due to intolerance...Ropinirole was gradually discontinued over 4 weeks, and quetiapine was introduced... This case highlights the potential for DAs, including ropinirole, to induce OS in PD patients. Clinicians should remain vigilant for psychiatric side effects during PD treatment and consider timely intervention, including medication adjustment and antipsychotic therapy, to prevent severe psychosocial consequences."

Journal • CNS Disorders • Mental Retardation • Movement Disorders • Parkinson's Disease • Psychiatry

Real-world observations on neuroinflammation-related drug responses in Alzheimer's disease. (PubMed, J Alzheimers Dis) - "We identified neuroinflammation-specific drug responses by comparing HRs between individuals with and without neuroinflammation-related conditions.ResultsWe identified 0.4 million matched pairs of individuals with and without neuroinflammation-related conditions. We identified three drugs (levothyroxine [HR = 0.89], mirabegron [HR = 0.69], and ropinirole [HR = 0.81]) had a lower HR and two drugs (levetiracetam [HR = 1.19], and quetiapine [HR = 1.83]) had a higher HR in individuals with neuroinflammation-related conditions compared to without (false discovery rate <0.05).ConclusionsIn patients with neuroinflammation-related conditions, we identified drugs associated with lower risks (levothyroxine, mirabegron and ropinirole) and higher risks (levetiracetam and quetiapine) of AD incidence."

Journal • Real-world evidence • Addiction (Opioid and Alcohol) • Alzheimer's Disease • Cardiovascular • Cerebral Hemorrhage • CNS Disorders • Epilepsy • Hematological Disorders • Inflammation • Vascular Neurology

Sex-Related Differences in Dopamine Agonist Response in Restless Legs Syndrome: A PSG-Based Study (WSS 2025) - "Both pramipexole and ropinirole primarily act through D3 receptors, which exhibit sex-specific expression patterns. This differential expression may underlie the higher pharmacological response observed in women, particularly with respect to reductions in PLMS. These findings align with emerging research on sex differences in the pharmacokinetics and pharmacodynamics of cardiovascular therapies, underscoring the importance of considering sex as a critical factor in personalized medicine."

Cardiovascular • CNS Disorders • Movement Disorders • Restless Legs Syndrome • Sleep Disorder

Impact of Dopamine Agonists and Clonazepam on LMM and PLMS in RLS Patients (WSS 2025) - "Materials and A retrospective analysis was conducted on 51 drug-free adult RLS patients, divided into three groups: 33 received a DA (pramipexole or ropinirole), 15 received CLO, and 18 received a placebo. This study underscores the complexity of motor disturbances in RLS, highlighting that while DAs effectively reduce PLMS, they have limited impact on LMM, suggesting distinct underlying mechanisms for these motor activities. These findings emphasize the need for a more comprehensive therapeutic approach in RLS that addresses the full spectrum of motor abnormalities. The persistence of arousals and NREM sleep instability despite DA treatment further suggests the inadequacy of current therapies in fully resolving sleep disruptions in RLS."

Clinical • CNS Disorders • Movement Disorders • Restless Legs Syndrome • Sleep Disorder

Cross-matrix multi-omics profiling identifies host-microbe interactions and diagnostic signatures in bovine subclinical mastitis. (PubMed, Front Microbiol) - "Noteworthy correlations between specific metabolites (e.g., ropinirole, arachidonic acid) and microbial genera (e.g., Succinivibrionaceae UCG-001, Alistipes) highlight the complex host-microbiome-metabolite interplay associated with SCM. These findings provide new insights into the pathophysiology of SCM and identify candidate biomarkers for early detection. The integrative multi-omics approach adopted in this study offers a valuable framework for developing innovative diagnostic and therapeutic strategies to enhance dairy cow health and productivity."

Journal • Hematological Disorders

Ropinirole Functions Through a Dopamine Receptor D2-Independent Mechanism to Ameliorate Amyotrophic Lateral Sclerosis Phenotypes in TARDBP-Mutant iPSC-Derived Motor Neurons. (PubMed, J Neurochem) - "Further analyses revealed that ROPI corrected aberrant RNA splicing and restored the mRNA expression of mitochondrial proteins in a DRD2-independent manner. Our findings suggest that ROPI not only functions as a canonical DRD2 agonist but also has pleiotropic DRD2-independent effects, offering a novel avenue for treatment strategies that target multiple pathways involved in ALS pathology."

Journal • Amyotrophic Lateral Sclerosis • CNS Disorders • DRD2 • TARDBP

Optimized Design and Development of Ropinirole Loaded Nanoparticles for Restless Leg Syndrome. (PubMed, J Pharm Bioallied Sci) - "The current study points to the potential of Ropinirole-loaded nanoparticles as a delivery system for treating RLS. Further clinical studies are warranted to confirm these results and establish both short- and long-term safety and efficacy."

Journal • Movement Disorders • Restless Legs Syndrome • Sleep Disorder

Impulsive-compulsive behaviours and striatal neuroactivity in mildly parkinsonian rats under D2/3 agonist and L-DOPA treatment. (PubMed, NPJ Parkinsons Dis) - "Compared to both L-DOPA and vehicle, ropinirole elicited a distinct pattern of striatal neuroactivity, shifting the expression of a cellular activity marker from dorsolateral to centro-medial regions. Our results reveal quite distinct profiles of ICBs and striatal activation upon treatment with ropinirole or L-DOPA, providing clues of therapeutic relevance to Parkinson's ICBs."

Journal • Preclinical • CNS Disorders • Movement Disorders • Parkinson's Disease

Successful treatment of delusional infestation with dupilumab (SID 2025) - "Numerous systemic treatments were trialed, including ropinirole cessation, ivermectin (at the patient's request), diphenhydramine, doxepin, fluconazole, gabapentin, naltrexone, and quetiapine without improvement...The initiation of dupilumab resulted in a complete response following numerous ineffective treatment modalities, supporting the potential role of dupilumab for refractory DI. Larger studies are needed to establish dupilumab's role in psychodermatologic disorder management."

Late-breaking abstract • CNS Disorders • Dermatology • Movement Disorders • Pain • Parkinson's Disease • IL4R

Rabbit Syndrome: A Rare Iatrogenic Tremor Due to Discontinuation of Aripiprazole (APA 2025) - "Patient was initially managed with Effexor and Buspar for anxiety before switching to Lexapro and Abilify in 2020...Patient's Abilify was initially reduced to 5mg daily, Requip 1mg nightly for RLS and Concerta 54mg daily for ADHD...Management includes tapering off antipsychotics, switching medications, or using anticholinergics like Benztropine or Trihexiphenidyl. ß-blockers may also provide relief. Further research is necessary to better understand and treat Rabbit syndrome."

Preclinical • ADHD (Impulsive Aggression) • Attention Deficit Hyperactivity Disorder • CNS Disorders • Depression • Infectious Disease • Mood Disorders • Movement Disorders • Psychiatry • DRD2

THE TWILIGHT ZONE: A CASE REPORT OF DELAYED EMERGENCE AFTER GENERAL ANESTHESIA FOR A ROUTINE CYSTOSCOPY (ASRA-SPRING 2025) - "Her home medications prior to the procedure included diphenhydramine 25 mg, Imbruvica 140 mg, Flexeril 5 mg, Prazosin 2 mg, alprazolam 1 mg, zolpidem 10 mg, ropinirole 1 mg, Seroquel 100 mg...Induction was performed with propofol, fentanyl, rocuronium and maintenance with sevoflurane...She was reversed appropriately with sugammadex with qualitative TOF showing 4 twitches without fade prior to extubation...Our suspicion is that this patient may have suffered delayed emergence secondary to residual effects of volatile anesthetics or potentially secondary to a psychiatric disorder related to a catatonic response. Figure 1 displays a broad range of differential diagnoses to keep in mind when encountering a patient with DE."

Case report • Clinical • Anesthesia • Cardiovascular • Chronic Lymphocytic Leukemia • Chronic Obstructive Pulmonary Disease • CNS Disorders • Depression • Dyslipidemia • Gastroesophageal Reflux Disease • Hematological Malignancies • Hypertension • Immunology • Leukemia • Mental Retardation • Metabolic Disorders • Oncology • Pain • Psychiatry • Respiratory Diseases • Rheumatology • Type 2 Diabetes Mellitus

Evaluation of Ropinirole versus Apomorphine for Emesis Induction in Dogs. (PubMed, J Vet Emerg Crit Care (San Antonio)) - "ROP had a lower first-dose emetic success rate, a longer median time to the first emetic event, an increased occurrence of minor adverse events, and a higher frequency of protracted vomiting necessitating rescue therapy. These findings suggest APO is a clinically superior emetic agent for dogs presenting to the emergency department requiring rapid decontamination."

Journal • Anesthesia • Cardiovascular

Neurostimulant Use for Rehabilitation and Recovery After Stroke: A Narrative Literature Review. (PubMed, Stroke) - "The qualitative analysis included 34 trials testing the following neurostimulants: methylphenidate (n=6), amphetamines (n=8), memantine (n=2), modafinil (n=2), levodopa (n=14), amantadine (n=1), bromocriptine (n=3), and ropinirole (n=1). In conclusion, there are promising results of positive effects of neurostimulants with few side effects, though studies are limited by heterogeneous designs and small sample sizes. Neurostimulant efficacy must be assessed in conjunction with specific rehabilitation modalities as part of larger, well-designed studies to best understand their effects on impairment."

Journal • Cardiovascular • CNS Disorders • Cognitive Disorders • Depression • Fatigue • Psychiatry

Ophthalmic ropinirole is an equally effective emetic agent in healthy dogs compared to intravenous apomorphine. (PubMed, Front Vet Sci) - "Incidence of adverse effects was similar, with a higher incidence of ocular redness and protracted vomiting in the ropinirole group. These results suggest similar efficacy of ropinirole compared to apomorphine, with similar adverse effect rates."

Journal • Ophthalmology

Stellate Ganglion Block for Refractory Periodic Limb Movement Disorder: Case Report (AAN 2025) - "Patient tried heat therapy (somewhat helpful), Ropinirole (helpful, unable to tolerate due to GERD), gabapentin (unclear benefit), duloxetine (not helpful), valium (sometimes helpful, limited by excessive sedation), Botox (briefly helpful), pramipexole (too expensive), baclofen (not helpful)...Propriospinal myoclonus was also considered, and antiepileptic trial, ie, levetiracetam/clonazepam, was advised3. SGB for PLMD has not been previously described. In our case, SGB showed an extremely beneficial response for PLMD."

Case report • Clinical • Anesthesia • CNS Disorders • Gastroesophageal Reflux Disease • Movement Disorders • Musculoskeletal Pain • Neuralgia • Novel Coronavirus Disease • Pain • Post-traumatic Stress Disorder • Sleep Disorder

Levodopa and dopamine agonist phobia in Parkinson's Disease: - does it really matter? A survey on treatment patterns in Polish tertiary centres. (PubMed, Neurol Neurochir Pol) - "Levodopa remains the gold standard in PD treatment in tertiary movement disorder centres in Poland. Dopamine agonists formed the second most frequently prescribed group of medications; however, the observed low dosages of both levodopa and dopamine agonists may suggest a cautious approach by clinicians. Amantadine and MAO-B inhibitors (mainly rasagiline) constituted important elements of PD pharmacotherapy. The high prevalence of complex polytherapy underlines the complexity of PD management, the cautious use of single medication at high doses, and the need for personalised therapeutic strategies."

Journal • CNS Disorders • Movement Disorders • Parkinson's Disease • COMT

Drug utilization study of antiparkinsonian medication in Romania during 25 years. (PubMed, Front Pharmacol) - "Selegiline was the most used until 2017 (0.82 DDD/TID), when a decrease in use was observed and continued until 2022 (0.49 DDD/TID)...Ropinirole was the most used dopamine agonist (0.56 DDD/TID in 2022)...Amantadine utilization was mainly constant throughout the 25 years, with 0.32 DDD/TID prescribed in 2022...MAO-inhibitors utilization came in second and was followed by dopamine agonists. Observing the trend in antiparkinsonian medication utilization over time is essential for providing insights into their real-world use and uptake in a large population."

Journal • CNS Disorders • Movement Disorders • Parkinson's Disease • Psychiatry